joetheman (1,046 posts)
I asking and would like even Dr. Fauci to respond if he is around.
Why can't there be a 'warp speed' effort to produce monoclonal antibodies as there was for producing the vaccines? It appears that the antibody treatment, if you can get it early enough, saves lives and mitigates symptoms.
Were ignorance bliss, DUpipo would be among the most
blissed out people on earth!
Monoclonal antibody (mab) treatments were a part of
Operation Warp Speed, and Trumpian efforts before OWS came into being. Two have been authorized, AbCellera/Junshi/Eli Lilly's (currently paused) and Regeneron's. AbCellera's mab was a result from partnering in a DARPA project begun in 2018. DUpipo have ideologically convenient memories, but I'm sure a search of their threads about Trump's bout with Covid will find DUmmies howling in outrage that Trump received Regeneron's mab "cocktail" under Compassionate Use.
So, a little history of which
joetheman appears unaware:
January 28, 2020 - AbCellera is mobilizing its pandemic response platform against the outbreak of Covid-19;
https://www.abcellera.com/news/2020-01-abcellera-mobilizing-a-response-to-novel-coronavirusFebruary 4, 2020 - HHS, Regeneron Collaborate to Develop 2019-nCoV Treatment;
https://www.hhs.gov/about/news/2020/02/04/hhs-regeneron-collaborate-to-develop-2019-ncov-treatment.html ,
https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibodyMarch 12, 2020 - AbCellera and Eli Lilly announced an agreement to develop antibody products for treatment and prevention of COVID-19; part of a 2018 DARPA program with AbCellera;
http://lilly.mediaroom.com/2020-03-12-AbCellera-and-Lilly-to-Co-develop-Antibody-Therapies-for-the-Treatment-of-COVID-19 ,
https://www.msn.com/en-us/finance/companies/eli-lilly-joins-race-to-develop-coronavirus-treatment/ar-BB116BNRJune 1, 2020 - Eli Lilly and AbCellera announced patients have been dosed in the Phase 1 study of an antibody treatment to fight COVID-19;
http://lilly.mediaroom.com/index.php?s=9042&item=138053 ,
https://www.abcellera.com/news/2020-06-01-worlds-first-covid-19-clinical-trial-for-a-potential-monoclonal-antibody-treatmentJune 11, 2020 - Regeneron Pharmaceuticals started the first clinical trial of its dual antibody cocktail for prevention and treatment of COVID-19;
https://investor.regeneron.com/news-releases/news-release-details/regeneron-begins-first-clinical-trials-anti-viral-antibodyJuly 6, 2020 - Regeneron announced the start of a Phase 3 trial to evaluate whether its polyclonal antibody treatment will prevent infection among uninfected people who have had close exposure to a COVID-19 patient; Regeneron also moved into the Phase 2/3 portion of its Phase 1/2/3 trials of with hospitalized and non-hospitalized patients with COVID-19;
https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-start-regn-cov2-phase-3-covid-19-preventionJuly 7, 2020 - HHS and DOD announced an aggreement with Regeneron for commercial-scale manufacturing of the company’s COVID-19 anti-viral antibody treatment;
https://www.hhs.gov/about/news/2020/07/07/hhs-dod-collaborate-regeneron-large-scale-manufacturing-demonstration-project-covid-19-investigational-therapeutic-treatment.htmlAugust 3, 2020 - AbCellera announced that its antibody has begun Phase 3 clinical trials;
https://www.abcellera.com/news/2020-08-03-abcellera-provides-covid-19-program-update ,
http://lilly.mediaroom.com/2020-08-03-Lilly-Initiates-Phase-3-Trial-of-LY-CoV555-for-Prevention-of-COVID-19-at-Long-Term-Care-Facilities-in-Partnership-with-the-National-Institute-of-Allergy-and-Infectious-Diseases-NIAID , -
https://www.nih.gov/news-events/news-releases/nih-launches-clinical-trial-test-antibody-treatment-hospitalized-covid-19-patients ,
https://www.nih.gov/news-events/news-releases/nih-clinical-trial-test-antibodies-other-experimental-therapeutics-mild-moderate-covid-19September 16, 2020 - Eli Lilly announced the randomized, double-blind, placebo-controlled Phase 2 study of a Covid-19 neutralizing antibody improved viral clearance from Day 11 for the placebo group to Day 3 for those who received the antibody;
http://lilly.mediaroom.com/2020-09-16-Lilly-announces-proof-of-concept-data-for-neutralizing-antibody-LY-CoV555-in-the-COVID-19-outpatient-setting ,
https://www.abcellera.com/news/2020-09-16-interim-data-phase-2-clinical-trialsSeptember 17, 2020 - Eli Lilly and Amgen announced a global antibody manufacturing collaboration for Lilly's anti-COVID-19 antibody to significantly increase supply capacity;
http://lilly.mediaroom.com/2020-09-17-Lilly-and-Amgen-Announce-Manufacturing-Collaboration-for-COVID-19-Antibody-Therapies ,
https://www.amgen.com/media/news-releases/2020/09/lilly-and-amgen-announce-manufacturing-collaboration-for-covid-19-antibody-therapies/September 29, 2020 - Regeneron announced the first data from a seamless Phase 1/2/3 trial of its antibody cocktail showing it reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19;
https://investor.regeneron.com/index.php/news-releases/news-release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-andOctober 2, 2020 - Regeneron confirmed that REGN-COV2 Antibody treatment was provided to President Trump under Compassionate Use request;
https://investor.regeneron.com/index.php/static-files/fd58ba6a-f401-47b0-9d65-cfb01c313ec6October 7, 2020 - Regeneron requested EUA from the FDA for its REGN-COV2 antibody treatment for Covid-19;
https://investor.regeneron.com/static-files/6feab76b-176d-402d-bf30-d40462e68b7b ; additional test data submitted October 28,
https://investor.regeneron.com/index.php/news-releases/news-release-details/regenerons-covid-19-outpatient-trial-prospectively-demonstratesOctober 7, 2020 - Eli Lilly announced that in Phase 2 trials combination therapy with two of Lilly's and AbCellera's SARS-CoV-2 neutralizing antibodies (LY-CoV555 and LY-CoV016) reduced viral load, symptoms and COVID-related hospitalization and ER visits; in monotherapy, a 700 mg dose of LY-CoV555 produced similar clinical effects; Phase 3 testing began August 3rd based on the combination therapy and monotherapy data, Lilly has submitted a request to the FDA for EUA for monotherapy and will submit a request for EUA for combination therapy in November;
http://lilly.mediaroom.com/index.php?s=9042&item=138100October 28, 2020 - Eli Lilly announced an initial agreement with the US government to supply 300,000 doses of bamlanivimab (LY-CoV555), an investigational neutralizing antibody, for $375 million if it is granted an EUA by the FDA; Lilly submitted a request for an EUA for mild to moderate COVID-19 in high-risk patients in early October; the agreement is for delivery over the two months following an EUA plus an option for the purchase of up to an additional 650,000 doses through June 30, 2021, under the same terms;
http://lilly.mediaroom.com/index.php?s=9042&item=138111 ,
https://www.hhs.gov/about/news/2020/10/28/hhs-dod-collaborate-plans-purchase-lilly-investigational-therapeutic-treat-covid-19.htmlNovember 09, 2020 - The FDA) today granted Emergency Use Authorization for Eli Lilly and Company's neutralizing antibody bamlanivimab (LY-CoV555) 700 mg; it is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test who are at high risk for progressing to severe COVID-19 and/or hospitalization; 300,000 doses were also purchased by the US government;
http://lilly.mediaroom.com/index.php?s=9042&item=138119 ,
https://www.abcellera.com/news/2020-11-09-bamlanivimab-us-fda-eua ,
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19November 21, 2020 - Regeneron's cocktail of monoclonal antibodies, REGN-COV2, received EUA from the FDA; there is an existing contract for Regeneron to supply 300,000 doses to the US government;
https://investor.regeneron.com/index.php/news-releases/news-release-details/regenerons-regen-cov2-first-antibody-cocktail-covid-19-receive ,
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19If DUmmie
joetheman really is unaware of
all of this, maybe DUmmies' refusal to see news they don't want to know or be known is the cause of that apparent ignorance. OWS' main focus was the vaccines, but mab treatments were boosted by OWS as well.
I will acknowledge, however, that GlaxoSmithKilne/Vir Biotechnology and AstraZeneca both have mab treatments in testing (GSK's being version 2.0, not yet being tested with humans), but I've not heard of any
LIEden administration actions relative to those mab treatments.
